An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models

Toxicology Letters

Volumn 121, Issue 2, 2001, Pages 97-106

  Ogawa, Tetsuo ^a   Mimura, Yuuichi ^a   Isowa, Koichi ^b   Kato, Hitomi ^a   Mitsuishi, Mikio ^b   Toyoshi, Tohru ^b   Kuwayama, Noriyuki ^a   Morimoto, Hideki ^a   Murakoshi, Masanori ^a   Nakayama, Takaharu ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b JBC Inc   (Japan)

Author keywords

Antimicrotubule agent; Dolastatin; Neurotoxicity; Paclitaxel; TZT 1027; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN PE; DOLASTATIN 10 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; MALE; MICROTUBULE; MOUSE; MYELINATED NERVE; NERVE FIBER DEGENERATION; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RABBIT; SENSORY NERVE;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORING AGENTS; HEMATOXYLIN; MALE; MICE; MICROTUBULES; MODELS, ANIMAL; OLIGOPEPTIDES; OSMIUM TETROXIDE; PACLITAXEL; PERIPHERAL NERVES; RABBITS; SCIATIC NERVE; SPINAL CORD; TOLONIUM CHLORIDE; VINCRISTINE;

EID: 0035971541     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00327-7     Document Type: Article

References (33)

1. Anderson T.D., Davidovich A., Arceo R., Brosnan C., Arezzo J., Schaumburg H. Peripheral neuropathy induced by 2′,3′-dideoxycytidine. A rabbit model of 2′,3′-dideoxycytidine neurotoxicity. Lab. Invest. 66:1991;63-74.
2. Apfel S.C., Lipton R.B., Arezzo J.C., Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Ann. Neurol. 29:1991;87-90.
3. Boyle F.M., Wheeler H.R., Shenfield G.M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Ther. 279:1996;410-415.
4. Bregman C.L., Buroker R.A., Hirth R.S., Crosswell A.R., Durham S.K. Etoposide- and BMY-40481-induced sensory neuropathy in mice. Toxicol. Pathol. 22:1994;528-535.
5. Cascino T. Clinical neurotoxic concerns on antineoplasic agents. Chang L.W., Slikker W. Jr, . Neurotoxicology Approaches and Methods. 1995;657-670 Academic Press, San Diego.
6. De Arruda M., Cocchiaro C.A., Nelson C.M., Grinnell C.M., Janssen B., Haupt A., Barlozzari T. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res. 55:1995;3085-3092.
7. Fiori M.G., Schiavinato A., Lini E., Nunzi M.G. Peripheral neuropathy induced by intravenous administration of vincristine sulfate in the rabbit. Toxicol. Pathol. 23:1995;248-255.
8. Gottschalk P.G., Dyck P.J., Kiely J.M. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology. 18:1968;875-882.
9. Green L.S., Donoso J.A., Heller-Bettinger I.E., Samson F.E. Axonal transport disturbances in vincristine-induced peripheral neuropathy. Ann. Neurol. 1:1977;255-262.
10. Holland J.F., Scharlau C., Gailani S., Krant M.J., Olson K.B., Horton J., Shnider B.I., Lynch J.J., Owens A., Carbone P.P., Colsky J., Grob D., Miller S.P., Hall T.C. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 33:1973;1258-1264.
11. Jackson D.V. Jr, Rosenbaum D.L., Carlisle L.J., Long T.R., Wells H.B., Spurr C.L. Glutamic acid modification of vincristine toxicity. Cancer Biochem. Biophys. 7:1984;245-252.
12. Kobayashi M., Natsume T., Tamaoki S., Watanabe J., Asano H., Mikami T., Miyasaka K., Miyazaki K., Gondo M., Sakakibara K., Tsukagoshi S. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn. J. Cancer Res. 88:1997;316-327.
13. Krug L.M., Miller V.A., Kalemkerian G.P., Kraut M.J., Ng K.K., Heelan R.T., Pizzo B.A., Perez W., McClean N., Kris M.G. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann. Oncol. 11:2000;227-228.
14. Legha S.S. Vincristine neurotoxicity. Pathophysiology and management. Med. Toxicol. 1:1986;421-427.
15. Lipton R.B., Apfel S.C., Dutcher J.P., Rosenberg R., Kaplan J., Berger A., Einzig A.I., Wiernik P., Schaumburg H.H. Taxol produces a predominantly sensory neuropathy. Neurology. 39:1989;368-373.
16. Mimura Y., Kato H., Eguchi K., Ogawa T. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology. 21:2000;513-520.
17. Miyazaki K., Kobayashi M., Natsume T., Gondo M., Mikami T., Sakakibara K., Tsukagoshi S. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem. Pharm. Bull. 43:1995;1706-1718.
18. Mross K., Herbst K., Berdel W.E., Korfel A., von Broen I.M., Bankmann Y., Hossfeld D.K. Phase I clinical and pharmacokinetic study of LU103793 (cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. Onkologie. 19:1996;490-495.
19. Natsume T., Watanabe J., Tamaoki S., Fujio N., Miyasaka K., Kobayashi M. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn. J. Cancer Res. 91:2000;737-747.
20. Norido F., Finesso M., Fiorito C., Marini P., Favaro G., Fusco M., Tessari F., Prosdocimi M. General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in the rabbit. Toxicol. Appl. Pharmacol. 93:1988;433-441.
21. Ochs S., Worth R. Comparison of the block of fast axoplasmic transport in mammalian nerve by vincristine, vinblastine and desacetyl vinblastine amide sulfate (DVA). Proc. Am. Assoc. Cancer Res. 16:1975;70.
22. Ogawa T., Mimura Y., Kato H., Ootsubo S., Murakoshi M. The usefulness of rabbits as an animal model for the neuropathological assessment of neurotoxicity following the administration of vincristine. Neurotoxicology. 21:2000;501-512.
23. Pettit G., Kamano Y., Dufresne C., Cerny R.L., Herald C.L., Schmidt J.M. Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J. Org. Chem. 54:1989;6005-6006.
24. Pitot H.C., McElroy E.A. Jr, Reid J.M., Windebank A.J., Sloan J.A., Erlichman C., Bagniewski P.G., Walker D.L., Rubin J., Goldberg R.M., Adjei A.A., Ames M.M. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. 5:1999;525-531.
25. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des. 5:1999;139-162.
26. Postma T.J., Vermorken J.B., Liefting A.J.M., Pinedo H.M., Heimans J.J. Paclitaxel-induced neuropathy. Ann. Oncol. 6:1995;489-494.
27. Rowinsky E.K., Donehower R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharm. Ther. 52:1991;35-84.
28. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82:1990;1247-1259.
29. Sahenk Z., Brady S.T., Mendell J.R. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 10:1987;80-84.
30. Todd G.C., Gibson W.R., Morton D.M. Toxicology of vindesine (desacetyl vinblastineamide) in mice, rats and dogs. J. Toxicol. Environ. Health. 1:1976;843-850.
31. Villalona-Calero M.A., Baker S.D., Hammond L., Aylesworth C., Eckhardt S.G., Kraynak M., Fram R., Fischkoff S., Velagapudi R., Toppmeyer D., Razvillas B., Jakimowicz K., Von Hoff D.D., Rowinsky E. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J. Oncol. 16:1998;2770-2779.
32. Weiss H.D., Walker M.D., Wiernik P.H. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N. Engl. J. Med. 291:1974;75-81.
33. Weiss H.D., Walker M.D., Wiernik P.H. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N. Engl. J. Med. 291:1974;127-133.